Leflunomid Aristo

Leflunomide, the active ingredient in Leflunomid Aristo, is an immunomodulatory agent (DMARD) presented as an oral dosage form for oral administration. It is used to manage rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce disease activity and joint damage.

GNH USA supplies Leflunomid Aristo as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and providing reliable worldwide distribution to hospitals, pharmacies and clinics. The company supports procurement teams with regulatory documentation, shipping logistics and post‑sale service.

Leflunomide, a disease‑modifying antirheumatic drug, acts on the immune system to control inflammatory arthritis.

- Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage. - Psoriatic arthritis: improves skin and joint symptoms while limiting disease progression.

Leflunomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: loose stools or increased bowel movements. - Nausea: feeling of sickness or urge to vomit. - Elevated liver enzymes: increase in ALT/AST levels. - Alopecia: thinning or loss of hair. - Rash: skin redness or irritation.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Teratogenicity: potential to cause fetal harm if exposure occurs during pregnancy.

Before prescribing Leflunomid Aristo, clinicians should consider several safety precautions and monitoring requirements.

- Pregnancy contraindication: avoid use in pregnant women; teratogenic risk is high. - Liver function monitoring: check baseline and periodic ALT/AST levels during therapy. - Blood pressure assessment: monitor for hypertension, especially in patients with cardiovascular risk. - Hematologic surveillance: perform regular complete blood counts to detect bone marrow suppression. - Live vaccine avoidance: do not administer live vaccines while on treatment. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Leflunomide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Methotrexate: enhanced toxicity, especially hepatic. - Cholesterol‑binding resins (e.g., cholestyramine): markedly reduce leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - TNF‑α inhibitors: potential for increased infection risk. - Oral contraceptives: reduced hormonal efficacy, consider alternative contraception.